Results 51 to 60 of about 2,242,189 (260)

Increased STAT1 signaling in endocrine-resistant breast cancer [PDF]

, 2014
Funding: China Scholarship Council, University of Edinburgh, Scottish Funding Council and Breakthrough Breast Cancer.Proteomic profiling of the estrogen/tamoxifen-sensitive MCF-7 cell line and its partially sensitive (MCF-7/LCC1) and fully resistant (MCF-
Thomas Jeremy S., Faratian Dana, Huang Rui, Sims Andrew H., Dana Faratian (171110), Simon P. Langdon, Danielle Wilson (550968), David J. Harrison (171106), Jeremy S. Thomas, Dana Faratian, Rui Huang, Wilson Danielle, Harrison David J., David J. Harrison, Danielle Wilson, Simon P Langdon, Thomas, Jeremy S, Sims, Andrew H, Andrew H. Sims (108040), Harrison, David J, Rui Huang (141490), Huang, Rui, Simon P. Langdon (207293), Wilson, Danielle, David J Harrison, Thomas, Jeremy, Langdon Simon P., Faratian, Dana, Andrew H. Sims, Andrew H Sims, Jeremy S Thomas, Jeremy S. Thomas (550969), Langdon, Simon P   +32 more
core   +2 more sources

Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas [PDF]

Anti-Cancer Drugs, 2015
Tamoxifen, a selective estrogen receptor modulator, is widely used in the chemotherapy of estrogen receptor-positive breast cancer. Recent studies have indicated that tamoxifen might have a potential chemotherapeutic effect on glioma. In the present study, we determined the chemotherapeutic action of tamoxifen on human glioma cell lines. Methylation of
Weiliang, He, Ran, Liu, Shao-Hua, Yang, Fang, Yuan   +3 more
openaire   +2 more sources

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker   +2 more
core   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.

PLoS ONE, 2019
BACKGROUND:Adjuvant endocrine treatment improves survival after estrogen receptor (ER) positive breast cancer. Recurrences occur, and most patients with metastatic breast cancer develop treatment resistance and incurable disease. An influential factor in
Annika Jögi, Anna Ehinger, Linda Hartman, Sara Alkner   +3 more
doaj   +1 more source

MTDH Mediates Estrogen-Independent Growth and Tamoxifen Resistance by Down-Regulating PTEN in MCF-7 Breast Cancer Cells

Cellular Physiology and Biochemistry, 2014
Background: About 70% of human breast cancers express estrogen receptor α (ERα) and in this kind of breast cancer estrogen plays an important role. Estrogen independent growth has been reported to promote resistance to one of the selective estrogen ...
Chunyuan Xu, Xiaoli Kong, Haiji Wang, Ning Zhang, Xiangnan Kong, Xia Ding, Xiaoyan Li, Qifeng Yang   +7 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. [PDF]

, 2013
OBJECTIVE: To evaluate evidence on the association between CYP2D6 genotype and tamoxifen response through. DESIGN: Systematic review and meta-analysis of prospective, cross-sectional and case-control studies published to 2012.
Danny W. K. Lum, Perel, P, Aroon D. Hingorani (142610), Holmes, Michael V, Danny W. K. Lum (465585), Michael V. Holmes, Perel, Pablo, Holmes, MV, Aroon D Hingorani, Hingorani, AD, Michael V Holmes, Pablo Perel (102217), Hingorani, Aroon D, Danny W K Lum, Pablo Perel, Lum, Danny WK, Aroon D. Hingorani, Lum, DW, Michael V. Holmes (256443)   +18 more
core   +1 more source

Tamoxifen-induced limb and craniofacial malformations.

, 2021
Along with representative vehicle controls of forelimb (a), hindlimb (f), and palate (i’), examples of malformations in forelimbs (b-e), hindlimbs (g, h), and palate (j’) of 200 mg/kg tamoxifen-treated animals are shown at GD17.
Austin C. Steward (11285743), Miranda R. Sun (9467987), Alexander A. Martin (11285746), Emma A. Sweet (4252480), Robert J. Lipinski (9468002)   +4 more
core   +1 more source